Despite prevailing financial market turbulence during the first quarter of 2015, it did not impede the ability of biotechs to raise capital. The period was characterized by a tsunami of cash flooding into their coffers. Both global public and private companies benefited from investors' seemingly insatiable appetite for their offerings. Read More
Coming off a banner year for venture capital deals, the first quarter report card dispelled any notions that investor "fatigue" might set in. In fact, private companies set a torrid pace, raising more than $2 billion, double the amount generated in the same period last year. Read More
As the curtain closed on the first quarter of the year, the report card performance numbers weren't pretty, as ongoing energy price ebbs and flows coupled with mixed domestic economic data kept the general markets on edge. As a result, the Dow Jones Industrial Average closed flat for the quarter and down 1.2 percent for the month of March. The Nasdaq Composite index did a little better, posting a 3.5 percent gain for the quarter but was down 0.5 percent in March. Read More
